Medications | Initial treatment | Cumulative treatment | ||||
---|---|---|---|---|---|---|
Early treatment (n=121) % |
Late treatment (n=266) % |
p value | Early treatment (n=121) % |
Late treatment (n=266) % |
p value | |
NSAIDs | 52.9 | 59.0 | 0.259 | 84.3 | 86.8 | 0.503 |
Corticosteroids | 50.4 | 48.9 | 0.779 | 73.3 | 79.0 | 0.224 |
Conventional DMARDs | ||||||
Methotrexate | 57.8 | 63.0 | 0.334 | 83.5 | 86.5 | 0.438 |
Hydroxychloroquine | 40.8 | 34.1 | 0.205 | 57.0 | 53.4 | 0.505 |
Sulfazalazine | 5.8 | 4.9 | 0.730 | 15.7 | 16.5 | 0.836 |
Leflunomide | 0.0 | 1.1 | 0.241 | 3.3 | 5.3 | 0.397 |
Azathioprine | 0.0 | 1.1 | 0.240 | 2.5 | 4.1 | 0.415 |
Cyclophosphamide | 0.0 | 0.0 | --- | 0.8 | 0.8 | 0.938 |
Gold salts | 4.1 | 2.7 | 0.450 | 7.4 | 8.7 | 0.689 |
Biologic agents | ||||||
TNF-α blockers | 10.7 | 11.6 | 0.794 | 52.1 | 48.5 | 0.515 |
Abatacept | 0.0 | 0.8 | 0.341 | 5.0 | 7.5 | 0.351 |
Rituximab | 0.0 | 0.0 | --- | 0.0 | 0.8 | 0.339 |
Tocilizumab | 0.0 | 0.0 | --- | 0.8 | 0.0 | 0.138 |
Small molecules | ||||||
Tofacitinib | 0.0 | 0.0 | --- | 0.0 | 0.38 | 0.499 |
Drug combinations | ||||||
NSAIDs + DMARDs | 50.4 | 56.0 | 0.305 | 80.2 | 84.2 | 0.327 |
NSAIDs + biologics | 4.1 | 3.8 | 0.860 | 44.6 | 41.7 | 0.593 |
Corticosteroids + DMARDs | 47.1 | 47.0 | 0.983 | 67.8 | 75.6 | 0.109 |
Corticosteroids + biologics | 5.0 | 3.4 | 0.457 | 38.8 | 41.4 | 0.641 |
DMARDs + biologics | 5.0 | 4.2 | 0.714 | 47.1 | 44.0 | 0.567 |